Alembic Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 06, 2025.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 0.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alembic Pharmaceuticals reported FY25 consolidated revenue from operations of Rs. 6,672.08 crores, up about 7% from Rs. 6,228.63 crores last year. Consolidated profit after tax fell roughly 5% to Rs. 583.42 crores, while on a standalone basis, PAT dropped about 24.5% to Rs. 503.12 crores. Consolidated EPS was Rs. 29.68 (vs Rs. 31.33) and operating cash flow fell sharply to Rs. 87.97 crores from Rs. 803.20 crores due to higher working capital. The Board recommended an unchanged dividend of Rs. 11 per share (550%). Statutory auditor K.C. Mehta & Co LLP's term ended and KKC & Associates LLP was appointed for five years; the outgoing auditor issued an unmodified opinion on the results.
Mixed bag for shareholders: revenue grew modestly but profitability slipped, especially standalone, and short-term borrowings more than doubled (debt-equity ratio rose from 0.09 to 0.23). The maintained dividend offers some comfort, but the steep drop in operating cash flow and margin compression could weigh on the stock in the near term.